FG Links Inability To Produce First Local COVID-19 Vaccine To $1.5m Clinical Trial Cost

The Federal Government says the uncertainty over the ability to raise $1.5 million cost of clinical trial is responsible for the delay in the local production of COVID-19 vaccine.

The Minister of Health, Dr Osagie Ehanire, said this on Thursday at the ministerial media briefing organised by the Presidential Communication Team at the State House, Abuja.

Dr  Ehanire said a Nigerian researcher had developed a COVID-19 vaccine candidate with a high probability to succeed but the cost of clinical trial has become an obstacle.

The minister, who wondered how to secure the $1.5 million needed to fulfill all the stages of the trial, said government might have to look for sponsors who would recoup their investment when the vaccine is successful.

Ehanire, who was asked about the progress on local vaccine production, said: “There is no personal interest in this. There are at least two, perhaps even three, Nigerian laboratories that have developed what you call vaccine candidates.

READ  Imo Govt Advises Residents To Adhere To Covid-19 Protocols To Avert Second Wave

“In fact, yesterday, we also talked to a fourth Nigerian laboratory, based in Maryland, USA, he has also produced his own vaccine candidate. A vaccine candidate means that you have already been able to get the antigen, you have produced something that will work.

“Now, you have to do what is called the clinical trials; clinical trial means you go through testing it that it’s safe. First of all, if it’s safe, it doesn’t cause a problem. Secondly, that it does what it promises to do; generate antibodies in your system. Okay.

“So, you go through those clinical trials, which are very detailed and they are expensive.

“One of our researchers here, who has produced such a candidate, I asked him, how much do you think you’ll need to go through these clinical trials; phase one, phase two, phase three? At least $1.5 million.

READ  Ebola virus returns back in Congo Says WHO

“That’s a lot. Do we have that now to test a vaccine?

“Well, we say we look for sources where we can get the sponsors, because the sponsorship is what you need.

“What some people do is that they invest in it and then once you produce the vaccine it’s successful, they buy it and that means you are done. But if it turns out not to have worked, your money is gone.

“It’s hard to find a way to sponsor these clinical trials because the are expensive and they have a very good chance of being successful, but some of them also have a good chance of not being able to see strong enough you know, the trick of efficacy. The efficacy means how well it works.

READ  Lassa fever kills 70 in 26 states, says NCDC

“So, we want to support our own vaccine and do the necessary to make sure they come out, but we are looking for the funds to support and also the necessary technical and whatever other backings that are required to get them to a level where they can… not only shall we be proud, it will be cheaper for us, we can be able to export also.

“So, we are looking at that, we’re looking for it and that’s in fact our preference. We know that those who are producing a vaccine now, we are at their mercy and I’ve said before that even if you have money now, you may not even get your vaccine.”

Recommended For You

Leave a Reply